1. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
- Author
-
Juan M. Falcón-Pérez, Jose Luis Calleja, Carolina Blanco, Juan G. Abraldes, Rafael Bañares, Joan Genescà, Eldimar Alvarado, Beatriz Peñas, Rosa Maria Morillas, Agustín Albillos, Jaime Bosch, Felix Royo, Maria Laura Garcia-Bermejo, Salvador Augustin, Ana García García de Paredes, Càndid Villanueva, Nicolò Manicardi, Carlos Ferre Aracil, Jordi Gracia-Sancho, Maria A. Poca, Juan Carlos García-Pagán, Institut Català de la Salut, [Garcia Garcia de Paredes A] Gastroenterology and Hepatology Department, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Universidad de Alcala, Madrid, Spain. [Villanueva C] Hospital of Santa Creu and Sant Pau, Autonomous University of Barcelona, Hospital Sant Pau Biomedical Research Institute (IIB Sant Pau) Barcelona, Spain. Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Spain. [Blanco C] Biomarkers and Therapeutic Targets Group, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain. [Genescà J] Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Spain. Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Manicardi N] Liver Vascular Biology Research Group, IDIBAPS Biomedical Research Institute, Barcelona, Spain. [Garcia-Pagan JC] Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Spain. Barcelona Hepatic Haemodynamic Laboratory, Liver Unit, Institute of Digestive and Metabolic Diseases, August Pi i Sunyer Institute of Biomedical Research, Hospital Clínic, Barcelona, Spain. [Augustin S] Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Cirrhosis ,Haemodynamic response ,Portal venous pressure ,enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES] ,Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES] ,Ascites - Diagnòstic ,RC799-869 ,Gastroenterology ,ROC, receiver-operating characteristic ,Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores] ,Beta-blockers ,Ascites ,Other subheadings::/diagnosis [Other subheadings] ,Immunology and Allergy ,610 Medicine & health ,Portal hypertension ,Cirrosi hepàtica - Complicacions ,microRNA ,portal hypertension ,MicroRNA ,Diseases of the digestive system. Gastroenterology ,Biomarker (medicine) ,medicine.symptom ,medicine.medical_specialty ,Randomization ,Short Communication ,Otros calificadores::/diagnóstico [Otros calificadores] ,Placebo ,beta-blockers ,Internal medicine ,Internal Medicine ,medicine ,miRNAs, microRNAs ,NSBBs, non-selective beta-blockers ,HVPG, hepatic venous pressure gradient ,MicroARN ,Hepatology ,business.industry ,cirrhosis ,medicine.disease ,afecciones patológicas, signos y síntomas::procesos patológicos::ascitis [ENFERMEDADES] ,CSPH, clinically significant portal hypertension ,Ct, cycle threshold ,business ,Pathological Conditions, Signs and Symptoms::Pathologic Processes::Ascites [DISEASES] ,Other subheadings::Other subheadings::/complications [Other subheadings] - Abstract
Background & Aims Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis. Methods Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year. Results Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59–0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53–0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year. Conclusions Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development. Lay summary Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites., Graphical abstract, Highlights • miR-181b-5p appears to be a useful serum biomarker to anticipate ascites onset. • Low serum miR-181b-5p indicates low risk of ascites in compensated cirrhosis. • Low serum miR-429 reflects acute hemodynamic response to non-selective beta-blockers.
- Published
- 2021